Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892580 · ClinicalTrials.gov registry record
Biomarker and DNA Collection in Subjects Participating in Protocol 22003
A clinical trial, sponsored by Seaside Therapeutics.
- Completed
- Registry status
- 32
- Enrollment target
NCT00892580: Completed study, sponsored by Seaside Therapeutics.
NCT00892580 is a clinical trial that has completed, run by Seaside Therapeutics. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00892580 has completed, sponsored by Seaside Therapeutics.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003 will be offered participation in 22003A which will evaluate secreted protein before and after treatment with STX209 and placebo to determine if they correlate with effectiveness of treatment or susceptibility to treatment with STX209. These same subjects will also be asked to contribute a blood sample for DNA (deoxyribonucleic acid) collection. The investigators will study the DNA to determine if STX209 works better in people with specific gene variations, or to find new gene variations that predict how well STX209 works.
Interventions
- DRUG STX209
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892580
The ClinicalTrials.gov registry entry for NCT00892580 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seaside Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STX209 is the first listed.
NCT00892580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00892580 about?
NCT00892580 is a clinical study titled "Biomarker and DNA Collection in Subjects Participating in Protocol 22003". The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003 will be offered participation in 22003A which will evaluate secreted protein before and after treatment with STX209 and placebo to determine if they correlate with effectiveness of treatment or s...
What is the current status of trial NCT00892580?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2009-05.
What interventions are being tested in trial NCT00892580?
The interventions under investigation include: STX209 (DRUG).
Who is sponsoring clinical trial NCT00892580?
This trial is sponsored by Seaside Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.